The latest market intelligence study Brachial plexus injuries market 2020 Report in healthcare relies on the statistics derived from both primary and secondary research
The brachial plexus is a network of nerves formed by intercommunication between the ventral roots of the lower four cervical nerves and the first thoracic nerves. Plexus are responsible to pass nerve signals to all the muscles of upper extremity.
The Brachial Plexus Injury’s Market report explores the Nonsteroidal anti-inflammatory drugs, Anticonvulsants, Tricyclic antidepressants and Analgesics. Nonsteroidal anti-inflammatory drugs is segmented is sub-segmented into celecoxib and naproxen.
Anticonvulsants is segmented is sub-segmented into gabapentin. Tricyclic antidepressants is segmented is sub-segmented into nortriptyline and doxepin.
Analgesics is segmented is sub-segmented into methadone, oxycodone and others.
Brachial plexus injury occurs when the nerves are stretched or compressed. In severe cases, the nerves may be torn away from the spinal cord.
Minor brachial plexus injury may result due to sport injuries such as football. The injuries can be treated by surgical procedure that would help to restore the functions of the nerves.
Increase in number of road accidents and sport injuries, availability of treatment options and growing demand for sports medicine are major drivers for the growth of this market. Furthermore, increase in the participation of adults in high energy sports also boosts the market growth.
Presence of large number of market players may restrict the entry of new players. The global brachial plexus injury market is expected to grow at a CAGR of 12.5% during the forecast period.
Brachial Plexus Injurys Market Regional Analysis:
Globally North America is the largest Brachial Plexus Injurys Market in the world. Europe is expected to be the second-largest market.
Furthermore Asia pacific market is expected to be the fastest growing market for Brachial Plexus Injurys.
Brachial Plexus Injurys Market Key Players: Pfizer (U.S.), Abbvie Inc. (U.S.), Johnson & Johnson (U.S.), GlaxoSmithKline (U.S.), Merck Sharp & Dohme Corp (U.S.), Novartis AG (Germany), F.
Hoffmann-La Roche Ltd (Switzerland), Eli Lily and Company (U.S.), AstraZeneca (U.S.) and Amgen (U.S.) .
Brachial Plexus Injurys Market by Regions: The American region accounts for the largest share of the global market due to flourishing growth of sports medicine and high rate of sport injures, which are important factors to boost the market. According the Center of Disease Control and Prevention, 8.6 million sports injuries were reported annually in the U.S.
Furthermore, rising survival rates of high speed motor vehicle collisions may increase the market for diagnosis and treatment of brachial plexus market. According to the Center of Disease Control and Prevention, more than 18,000 survive road accidents each year and received emergency treatment involving surgical procedures.
Europe is the second largest market that holds a noticeable share of the global brachial plexus injury market owing the availability of drugs for the treatment and an increase in the number of patients treated in emergency departments.
Asia Pacific is expected to be the fastest growing market owing to the high and ever increasing rates of traffic accidents in many of the Asia Pacific countries and the consequent demand for NSAIDs and other drugs. India is expected to be the largest market for Asia Pacific.
According to the data from the Government of India reports, the total number of road accidents increased by 2.5 per cent from 4,89,400 in 2014 to 5,01,423 in 2015.
In the Middle East & Africa, the market shows steady but positive growth due to the continuous growth of healthcare diagnostics.
About Market Research Future:
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which he